Engineered immune cells take on philadelphia Chromosome-Positive leukemia

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old, gender not restricted; 2. Subjects diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) in accordance with the 2016 WHO Classification of Acute Leukemias; 3. Abnormal B cells positive for CD19 and CD22 by immunophenotyping; 4. Subjects positive for Philadelphia chromosome (Ph chromosome) and BCR/ABL1 fusion gene by chromosomal and corresponding genetic testing; 5. Newly diagnosed B-ALL patients who have not received treatment with standard chemotherapy regimens; 6. Serum total bilirubin ≤ 51 μmol/L, serum ALT and AST both ≤ 3 times the upper limit of the normal reference range, and serum creatinine ≤ 176.8 μmol/L; 7. Left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiography; 8. Subjects with no active pulmonary infection and oxygen saturation ≥ 92% without oxygen supplementation; 9. Estimated survival time ≥ 3 months; 10. ECOG performance status score 0-2; 11. Females and males of childbearing potential must agree to use appropriate contraceptive measures before enrollment, during study participation, and within 6 months after infusion; 12. Subjects voluntarily participate in this study and sign the informed consent form. Exclusion Criteria: * Subjects meeting any of the following exclusion criteria are ineligible for enrollment in this study: 1. Subjects with a history of epilepsy or other central nervous system diseases; 2. Subjects with a prior history of QT interval prolongation or severe cardiac diseases; 3. Pregnant or lactating women (the safety of this therapy for unborn children is unknown); 4. Subjects with untreated active infections; 5. Subjects with serological evidence of chronic hepatitis B virus (HBV) infection who are unable or unwilling to receive standard prophylactic antiviral treatment, or have a detectable HBV viral DNA load; subjects with serological evidence of hepatitis C virus (HCV) infection who have not completed curative treatment or have a detectable HCV viral load; 6. Human immunodeficiency virus (HIV) antibody positive; 7. Syphilis antibody positive; 8. Subjects who have previously received any gene therapy products; 9. Subjects with other uncontrolled diseases who, in the investigator's judgment, are unsuitable for enrollment; 10. Any other conditions that, in the investigator's judgment, may increase the risk to the subject or interfere with the study results.